Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.76 |
| ▸ | RPS6KA1 | Q15418 | 16/20 | 0.76 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.76 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.76 |
| ▸ | AKT2 | P31751 | 10/20 | 0.73 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.73 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488629 | 0.98 | AKT1 (0.76) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| Trifluoroacetic Acid SCHEMBL3488230 | 0.89 | AKT1 (0.88) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| SCHEMBL5062859 | 0.87 | AKT1 (0.81) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| SCHEMBL5067574 | 0.87 | AKT1 (0.76) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| SCHEMBL13702486 | 0.87 | AKT1 (1.00) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| Trifluoroacetic Acid SCHEMBL3488625 | 0.87 | AKT1 (0.88) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| SCHEMBL5066280 | 0.87 | AKT1 (0.80) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| Trifluoroacetic Acid SCHEMBL5067578 | 0.85 | AKT1 (1.00) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| SCHEMBL3488233 | 0.85 | AKT1 (0.81) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062855 | 0.85 | AKT1 (0.90) | AKT1RPS6KA1ROCK1RPS6KA5AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | SMITHKLINE BEECHAM CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885ROCK1 478/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885ROCK1 478/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885ROCK1 478/4885 |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | MAP4K2, MAPKAPK2, PTK2B | AKT1 254/4885RPS6KA1 216/4885ROCK1 434/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885ROCK1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.